IRIDEX Corporation

IRIX Healthcare Medical Devices

IRIDEX Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, up 8.23% from fiscal 2024. In the quarter to June 2026, revenue fell 7.41%, EPS fell 16.7%, free cash flow grew 130.2% and total debt rose 3.27%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.81 0.01 −1.22%
Market cap
$14.5M
P/E
0.0×
Fwd P/E
−21.8×
Dividend yield
—
F-score
4/9
Altman Z
−1.95
Beneish M
−2.75
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
0.38 0.37 0.33 0.39
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(16.74) 32.78 (13.10) 115.12
P/B ratio
0.00 0.00 0.00 0.00
EV/Sales
0.38 0.36 0.35 0.40
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(4.83) (8.30) (7.26) (10.44)
Current Ratio
1.94 1.91 1.92 1.82
Net Debt/EBITDA
1.84 (5.25) (10.64) 1.39
Debt/Equity
0.79 0.76 0.80 1.04
Earnings Yield
(26.32%) (22.81%) (18.81%) (17.39%)
Free Cash Flow Yield
(20.57%) (11.70%) (14.49%) (9.98%)
Free Cash Flow per Share
(0.07) 0.03 (0.08) 0.01
Book value per Share
0.28 0.29 0.27 0.21
Free Cash Flow
(1.17) 0.48 (1.44) 0.12
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates